Oncodesign Precision Medicine (OPM) obtains €5.6 million in public funding for its DEMOCRITE program dedicated to the clinical development of OPM-101

Regulatory News:

Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancer, announced today that it has received notice of the grant of funding associated with the "i-Démo n°2" call for projects as part of the France 2030 plan. The aim of this call for projects is to develop industrial and service companies in growth markets that create value and competitiveness for our economy and contribute to the energy, ecological and digital transitions.

The government has allocated €5.6 M of funding to the DEMOCRITE program for a total project cost of €12.5 M. The funding will be provided as a grant (€1.7 M) and repayable advances (€3.9 M) for a project period of 43 months.

OPM-101, developed from the Nanocyclix platform, is currently being administered to the last healthy volunteer in phase I trial and is one of OPM's most advanced assets. The DEMOCRITE project, in response to bpifrance's

I-Démo n°2 call for projects, aims to demonstrate the efficiency of OPM-101 by targeting RIPK2 in Inflammatory Bowel Diseases. More specifically, this project aims to fund the end of phase 1 and phase 2a of our OPM-101 molecule for the treatment of Immune-Induced Ulcerative Colitis (IIUC).

IIUC are:

• An immunological adverse effect intrinsically linked to the action mechanism of immune checkpoint inhibitors (IPCI) represented by anti-CTLA4 & anti-PD(L)1,
• One of the most frequent and severe effects of IPCI, (particularly anti-CTLA4 (40% all grades) and anti-CTLA4 & anti-PD1 combinations (>30% all grades))

Furthermore, there are strong similarities between Recto Colitis Hemorrhagic (RCH) and IIUC. The main purpose of the DEMOCRITE project for OPM is to demonstrate proof of concept of the efficiency of OPM-101 in patients suffering from IIUC in order to reach a commercial agreement with a pharmaceutical partner, while continuing the development of OPM-101 for the treatment of UC.

OPM-101 is one of three molecules derived from our Nanocyclix kinase inhibitor technology administered to humans. Several other molecules are currently being optimized for known and unexplored kinases and will become tomorrow's targeted therapies in precision medicine. The success of the DEMOCRITE project will enable OPM to finance, develop and secure a precision medicine sector in France, positioning OPM as a leader in the development of kinase inhibitors.